Cargando…

Clinical study of ganshuang granule combined with tenofovir in the treatment of chronic hepatitis B complicated with nonalcoholic fatty liver disease

Objective: This study aims to investigate the clinical efficacy of Ganshuang granules combined with tenofovir, an antiviral drug, in the treatment of chronic hepatitis B complicated with nonalcoholic fatty liver disease. Methods: A total of 92 patients with chronic hepatitis B combined with non-alco...

Descripción completa

Detalles Bibliográficos
Autores principales:	Su, Changtian, Yang, Qin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9794573/ https://www.ncbi.nlm.nih.gov/pubmed/36588741 http://dx.doi.org/10.3389/fphar.2022.1032789

Ejemplares similares

Clinical efficacy and safety of Ganshuang granules as an adjuvant treatment for chronic hepatitis B liver fibrosis: A protocol for systematic review and meta analysis
por: Zeng, Shaoqian, et al.
Publicado: (2020)

Naringin in Ganshuang Granule suppresses activation of hepatic stellate cells for anti‐fibrosis effect by inhibition of mammalian target of rapamycin
por: Shi, Hongbo, et al.
Publicado: (2016)

Combined Use of Bicyclol and Berberine Alleviates Mouse Nonalcoholic Fatty Liver Disease
por: Li, Hu, et al.
Publicado: (2022)

Effectiveness and safety of tenofovir amibufenamide and its comparison with tenofovir alafenamide in patients with chronic hepatitis B: results from a retrospective real-world study
por: Li, Lanqing, et al.
Publicado: (2023)

Revealing the Mechanism of Huazhi Rougan Granule in the Treatment of Nonalcoholic Fatty Liver Through Intestinal Flora Based on 16S rRNA, Metagenomic Sequencing and Network Pharmacology
por: Liu, Yingying, et al.
Publicado: (2022)

The Role of Bone Morphogenetic Protein 9 in Nonalcoholic Fatty Liver Disease in Mice
por: Sun, Qin-Juan, et al.
Publicado: (2021)

Corrigendum: Revealing the mechanism of Huazhi Rougan granule in the treatment of nonalcoholic fatty liver through intestinal flora based on 16S rRNA, metagenomic sequencing and network pharmacology
por: Liu, Yingying, et al.
Publicado: (2023)

Recent evaluation about inflammatory mechanisms in nonalcoholic fatty liver disease
por: Song, Chong, et al.
Publicado: (2023)

Protective effect of phytoestrogens on nonalcoholic fatty liver disease in postmenopausal women
por: Zhao, ChenLu, et al.
Publicado: (2023)

The expression of thymosin β4 in chronic hepatitis B combined nonalcoholic fatty liver disease
por: Liang, Jing, et al.
Publicado: (2016)

Pharmacological Effects and Molecular Protective Mechanisms of Astragalus Polysaccharides on Nonalcoholic Fatty Liver Disease
por: Zhang, Jing, et al.
Publicado: (2022)

Editorial: Nonalcoholic fatty liver disease: From pathogenesis to phytomedicine based on omics technology
por: Ji, Guang, et al.
Publicado: (2022)

Targeting Liver Sinusoidal Endothelial Cells: An Attractive Therapeutic Strategy to Control Inflammation in Nonalcoholic Fatty Liver Disease
por: Wang, Xue-Kai, et al.
Publicado: (2021)

Untargeted Metabolomic Analysis of the Effects and Mechanism of Nuciferine Treatment on Rats With Nonalcoholic Fatty Liver Disease
por: Cui, Huantian, et al.
Publicado: (2020)

Transcriptomic Analysis Reveals the Protective Effects of Empagliflozin on Lipid Metabolism in Nonalcoholic Fatty Liver Disease
por: Ma, Yuting, et al.
Publicado: (2021)

Wendan decoction in the treatment of nonalcoholic fatty liver disease: A systematic review and meta-analysis
por: Zhang, Yufeng, et al.
Publicado: (2022)

Urine Assay to Measure Tenofovir Concentrations in Patients Taking Tenofovir Alafenamide
por: Lalley-Chareczko, Linden, et al.
Publicado: (2020)

Study on the Hepatoprotection of Schisandra chinensis Caulis Polysaccharides in Nonalcoholic Fatty Liver Disease in Rats Based on Metabolomics
por: Feng, Yanbo, et al.
Publicado: (2021)

Integrative evidence construction for resveratrol treatment of nonalcoholic fatty liver disease: preclinical and clinical meta-analyses
por: He, Xuan, et al.
Publicado: (2023)

Hepatitis B virus infection combined with nonalcoholic fatty liver disease: Interaction and prognosis
por: Liu, Lili, et al.
Publicado: (2023)

Distribution Evaluation of Tenofovir in the Breast Milk of Mothers With HBeAg-Positive Chronic HBV Infection After Treatment With Tenofovir Alafenamide and Tenofovir Disoproxil Fumarate by a Sensitive UPLC-MS/MS Method
por: Yang, Na, et al.
Publicado: (2021)

Hepatic Innervations and Nonalcoholic Fatty Liver Disease
por: Adori, Monika, et al.
Publicado: (2023)

The role of hepatic macrophages in nonalcoholic fatty liver disease and nonalcoholic steatohepatitis
por: Cha, Ji-Young, et al.
Publicado: (2018)

A New Endemic of Concomitant Nonalcoholic Fatty Liver Disease and Chronic Hepatitis B
por: Hanif, Hira, et al.
Publicado: (2020)

Ginsenosides Improve Nonalcoholic Fatty Liver Disease via Integrated Regulation of Gut Microbiota, Inflammation and Energy Homeostasis
por: Liang, Wenyi, et al.
Publicado: (2021)

Comprehensive transcriptomic analysis and meta-analysis identify therapeutic effects of N-acetylcysteine in nonalcoholic fatty liver disease
por: Yang, Keungmo, et al.
Publicado: (2023)

Nonalcoholic Fatty Liver Disease: Its Mechanisms and Complications
por: El Ouaamari, Abdelfattah, et al.
Publicado: (2013)

The impact of nonalcoholic fatty liver disease on chronic viral hepatitis – progression to cirrhosis
por: Olariu, Cristina, et al.
Publicado: (2013)

Ilexsaponin A(1) Ameliorates Diet-Induced Nonalcoholic Fatty Liver Disease by Regulating Bile Acid Metabolism in Mice
por: Zhao, Wen-wen, et al.
Publicado: (2021)

Interleukin-6 Receptor Blockade can Increase the Risk of Nonalcoholic Fatty Liver Disease: Indications From Mendelian Randomization
por: Li, Shuxuan, et al.
Publicado: (2022)

Editorial: Nonalcoholic fatty liver disease therapy: Exploring molecular mechanisms of well-defined composition from natural plants
por: Zhang, Wenji, et al.
Publicado: (2022)

Geniposide and Chlorogenic Acid Combination Improves Non-Alcoholic Fatty Liver Disease Involving the Potent Suppression of Elevated Hepatic SCD-1
por: Chen, Cheng, et al.
Publicado: (2021)

Combination Therapies for Nonalcoholic Fatty Liver Disease
por: Makri, Evangelia S., et al.
Publicado: (2022)

Metformin Alleviates Hepatic Steatosis and Insulin Resistance in a Mouse Model of High-Fat Diet-Induced Nonalcoholic Fatty Liver Disease by Promoting Transcription Factor EB-Dependent Autophagy
por: Zhang, Dan, et al.
Publicado: (2021)

Astragaloside IV Improves High-Fat Diet–Induced Hepatic Steatosis in Nonalcoholic Fatty Liver Disease Rats by Regulating Inflammatory Factors Level via TLR4/NF-κB Signaling Pathway
por: Liu, Ying-Li, et al.
Publicado: (2021)

Nonalcoholic Fatty Liver Disease in Chronic Hepatitis B and C Patients from Western Amazon
por: Nascimento, A. C. M., et al.
Publicado: (2012)

Similar Connotation in Chronic Hepatitis B and Nonalcoholic Fatty Liver Patients with Dampness-Heat Syndrome
por: Dai, Jianye, et al.
Publicado: (2013)

Adverse Effect of Nonalcoholic Fatty Liver Disease on the Therapeutic Response in Patients with Chronic Hepatitis B
por: Zhang, Siyu, et al.
Publicado: (2023)

Metabolic Syndrome, Nonalcoholic Fatty Liver Disease, and Chronic Hepatitis B: A Narrative Review
por: Diao, Yuting, et al.
Publicado: (2022)

Baseline hepatocyte ballooning is a risk factor for adverse events in patients with chronic hepatitis B complicated with nonalcoholic fatty liver disease
por: Tan, You-Wen, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_12jkl880ljhpop6udc3hcvi6g5